Influence of HLA Mismatching on Survival in Lung Transplantation

Hayes, Don; Whitson, Bryan A.; Ghadiali, Samir N.; Tobias, Joseph D.; Mansour, Heidi M.; Black, Sylvester M.

doi:10.1007/s00408-015-9768-9

Cited by 22 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The importance of HLA matching has been reported in a number of large observational studies, including the 2017 ISHLT report, and a 23,000-patient study reported by Hayes et al (Fig. 1) [2,55]. It is worth noting that, while Hayes et al employed a lower cut-off for HLA mismatch (< 3 vs ≥ 3), their study actually reported a lower hazard ratio for mortality compared to the ISHLT report, which suggests that having three HLA mismatch may not be associated with significantly worse outcome.…”

Section: Antigenic Matchingmentioning

confidence: 89%

Review 1: Lung transplant—from donor selection to graft preparation

et al. 2020

View full text Add to dashboard Cite

For various end-stage lung diseases, lung transplantation remains one of the only viable treatment options. While the demand for lung transplantation has steadily risen over the last few decades, the availability of donor grafts is limited, which have resulted in progressively longer waiting lists. In the early years of lung transplantation, only the 'ideal' donor grafts are considered for transplantation. Due to the donor shortages, there is ongoing discussion about the safe use of 'suboptimal' grafts to expand the donor pool. In this review, we will discuss the considerations around donor selection, donor-recipient matching, graft preparation and graft optimisation.

show abstract

Section: Antigenic Matchingmentioning

confidence: 89%

Review 1: Lung transplant—from donor selection to graft preparation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chimerism and HLA compatibility are hypothesized to be involved in the favorable results of LDLLT after allo-HSCT. 3,13,14 The recipients of LDLLT following allo-HSCT from the same donor may require little or no immunosuppressive therapy. [13][14][15] It has been reported that the rate of PTLD, as a complication of LDLLT after allo-HSCT, was 10.5% in Japan.…”

Section: Discussionmentioning

confidence: 99%

“…3,13,14 The recipients of LDLLT following allo-HSCT from the same donor may require little or no immunosuppressive therapy. [13][14][15] It has been reported that the rate of PTLD, as a complication of LDLLT after allo-HSCT, was 10.5% in Japan. 13 The incidence of de novo malignancy after lung transplantation, including PTLD, appeared to be higher in patients after allo-HSCT.…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder as a complication after cadaveric lung transplantation following allogeneic hematopoietic stem cell transplantation

Hoshino

Chen‐Yoshikawa

Nagasaka

et al. 2017

Journal of Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

IntroductionAmidst an increase in long-term survivors after allogeneic hematopoietic stem cell transplantation allo-HSCT , there has also been an increase in bronchiolitis obliterans BO , a lung lesion of chronic graft-versus-host disease chronic GVHD .1 The only curative therapy is lung transplantation, unfortunately solid organ transplantation after allo-HSCT is associated with a high likelihood of the development of advanced immunodeficiency. 2 This increases concern for the development of post-transplantation lymphoproliferative disorder PTLD . There are very few reported cases of cadaveric lung transplantation CLT after allo-HSCT in Japan. Although there is potential to reduce or even terminate immunosuppression with living-donor lobar lung transplantation using the same donor as for allo-HSCT, it is difficult to achieve this with CLT. An increase in the number of cases of CLT after allo-HSCT for BO is expected; therefore, it is necessary to pay attention to the complications associated with PTLD.

show abstract

“…21 Intriguingly, published studies have also provided conflicting evidence by demonstrating that the degree of HLA mismatching between donor and recipient may not impact lung allograft rejection. 22–26 This indicates the possibility of alternate immune mechanisms in mediating lung allograft rejection. 27,28 Emerging data from our laboratories and others have implicated the role of autoimmunity against lung-restricted self-antigens in the development of rejection following lung transplantation.…”

Section: Introductionmentioning

confidence: 98%

Lung Injury and Loss of Regulatory T Cells Primes for Lung-Restricted Autoimmunity

Akbarpour

Bharat

2017

Crit Rev Immunol

View full text Add to dashboard Cite

Lung transplantation is a life-saving therapy for several end-stage lung diseases. However, lung allografts suffer from the lowest survival rate predominantly due to rejection. The pathogenesis of alloimmunity and its role in allograft rejection has been extensively studied and multiple approaches have been described to induce tolerance. However, in the context of lung transplantation, dysregulation of mechanisms, which maintain tolerance against self-antigens, can lead to lung-restricted autoimmunity, which has been recently identified to drive the immunopathogenesis of allograft rejection. Indeed, both preexisting as well as de novo lung-restricted autoimmunity can play a major role in the development of lung allograft rejection. The three most widely studied lung-restricted self-antigens include collagen type I, collagen type V, and k-alpha 1 tubulin. In this review, we discuss the role of lung-restricted autoimmunity in the development of both early as well as late lung allograft rejection and recent literature providing insight into the development of lung-restricted autoimmunity through the dysfunction of immune mechanisms which maintain peripheral tolerance.

show abstract

Influence of HLA Mismatching on Survival in Lung Transplantation

Abstract: HLA mismatching is associated with increased hazard risk for death after LTx, while induction with basiliximab and other factors related to LTx reduce the risk.

Cited by 22 publications

References 27 publications

Review 1: Lung transplant—from donor selection to graft preparation

Review 1: Lung transplant—from donor selection to graft preparation

Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder as a complication after cadaveric lung transplantation following allogeneic hematopoietic stem cell transplantation

Lung Injury and Loss of Regulatory T Cells Primes for Lung-Restricted Autoimmunity

Contact Info

Product

Resources

About